TITLE

Hikal to Supply APIs for Pfizer in Bangalore

AUTHOR(S)
Ramesh, Deepti
PUB. DATE
January 2008
SOURCE
Chemical Week;1/7/2008, Vol. 170 Issue 1, p40
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the long-term agreement signed by Hikal Ltd., a manufacturer of active pharmaceutical ingredients (API) and intermediates in Mumbai, India, to contract manufacture and supply API for Pfizer. Hikal will manufacture the API at its U.S. Food and Development Authority (FDA)-approved facility at Jigani, near Bangalore. According to Jai Hiremath, vice chairman of Hikal, the agreement will have a substantial impact on the pharmaceutical business.
ACCESSION #
28618389

 

Related Articles

  • HIKAL CHIEF LOOKS AHEAD. Boswell, Clay // ICIS Chemical Business;1/28/2008, Vol. 273 Issue 4, p17 

    The article presents the views of Jai Hiremath, vice chairman and managing director of Mumbai, India-based fine chemical company Hikal Ltd., on the future of India's pharmaceutical manufacturing sector. Hiremath hopes that India will be the heart of pharmaceutical manufacturing. He attributed...

  • Degussa discovers India. Williams, Debe // Chemical Market Reporter;4/3/2006, Vol. 269 Issue 13, p19 

    The article analyzes the long-term non-exclusive manufacturing agreement for pharmaceutical intermediates and active pharmaceutical ingredients signed by Germany's Degussa and India's Hikal in early March 2006. The move is part of Degussa's strategy of deriving a double-digit percentage of its...

  • Hikal picks stake in Sinochem arm.  // Chemical Business;Dec2005, Vol. 19 Issue 12, p47 

    This article reports on a joint venture agreement signed by Hikal Ltd. by purchasing a minority stake in one of the subsidiaries of Sinochem Corp., as of December 2005. The terms of the agreement are presented. The benefits of the agreement to Hikal are highlighted. The views of Jai Hiremath,...

  • Hikal commissions Taloja plant.  // Chemical Business;Jul2008, Vol. 22 Issue 7, p72 

    The article reports on the commissioning of a multi-purpose agrochemical plant of Hikal Ltd. at Taloja in India in 2008. In a statement released by the company, vice-chairman and managing director Jai Hiremath mentioned that the plant will have a significant impact on Hikal's agrochemical...

  • Hikal Q4 net up at Rs 12.4 cr.  // Chemical Business;Jun2006, Vol. 20 Issue 6, p72 

    The article reports on the financial performance of India-based chemical manufacturer Hikal Ltd. for the fourth quarter ended March 31, 2006. Focus areas that have registered growth include the company's pharmaceutical initiatives and its agrochemicals business. Hikal posted an increase in net...

  • Hikal to invest Rs 200 crore to set up units.  // Chemical Business;Apr2008, Vol. 22 Issue 4, p87 

    The article reports on the plan of Mumbai, India-based contract research and manufacturing business Hikal to invest in establishing new manufacturing facilities in Bangalore and a research and development centre in Pune in 2008. The company has finalised an agreement with Bayer CropScience for...

  • Hikal eyes more acquisitions.  // Chemical Business;Jun2005, Vol. 19 Issue 6, p79 

    Reports on the acquisition plans of Hikal Ltd. as of June 2005. Significance of the acquisition to its financial performance; Advantages of its involvement in the pharmaceutical business; Outsourcing deal with a Japanese trading company.

  • Fine Chemical firms Seek Overseas Acquisitions. Scott, Alex // Chemical Week;9/26/2004, Vol. 166 Issue 32, p38 

    Focuses on the business plans of custom pharmaceutical intermediate companies in India. Plans of custom pharmaceutical intermediate companies to acquire U.S.- and European-based companies; Percentage of stake acquired by Hikal in pharmaceutical marketing and distribution firm Marsing & Co.;...

  • pharmaceuticals & fine chemicals.  // Chemical Week;3/9/2005, Vol. 167 Issue 8, p23 

    Presents international news briefs on the pharmaceutical and fine chemical industries as of March 9, 2005. Extension of the a contract between biotechnology firms Lonza and Biotest in Germany for the production of monoclonal antibody BT-061; Plan of agricultural chemicals and pharmaceutical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics